MENU
+Compare
AUPH
Stock ticker: NASDAQ
AS OF
Jun 27 closing price
Price
$8.64
Change
+$0.01 (+0.12%)
Capitalization
1.16B

AUPH Aurinia Pharmaceuticals Forecast, Technical & Fundamental Analysis

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs... Show more

Industry: #Biotechnology
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for AUPH with price predictions
Jun 27, 2025

AUPH in upward trend: price rose above 50-day moving average on June 26, 2025

AUPH moved above its 50-day moving average on June 26, 2025 date and that indicates a change from a downward trend to an upward trend. In of 43 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 26, 2025. You may want to consider a long position or call options on AUPH as a result. In of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for AUPH just turned positive on June 26, 2025. Looking at past instances where AUPH's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for AUPH crossed bullishly above the 50-day moving average on June 26, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AUPH advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AUPH broke above its upper Bollinger Band on June 26, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for AUPH entered a downward trend on June 25, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AUPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.333) is normal, around the industry mean (16.366). P/E Ratio (31.926) is within average values for comparable stocks, (58.189). AUPH's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (5.063) is also within normal values, averaging (252.247).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

AUPH is expected to report earnings to fall 10.00% to 14 cents per share on July 31

Aurinia Pharmaceuticals AUPH Stock Earnings Reports
Q2'25
Est.
$0.14
Q1'25
Beat
by $0.05
Q4'24
Missed
by $0.02
Q3'24
Beat
by $0.08
Q2'24
Est.
$0.01
The last earnings report on May 12 showed earnings per share of 15 cents, beating the estimate of 10 cents. With 4.37M shares outstanding, the current market capitalization sits at 1.16B.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on discovery and development of immunomodulating therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
14315 118 Avenue
Phone
+1 250 708-4272
Employees
300
Web
https://www.auriniapharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MCGFX13.320.09
+0.68%
AMG Montrusco Bolton Large Cap Growth N
MCLVX27.280.13
+0.48%
BlackRock Advantage Large Cap Val Inv C
AMGIX37.150.12
+0.32%
American Century Discplnd Cor Val I
SVAIX6.130.01
+0.15%
Federated Hermes Strategic Value Div IS
CMPCX19.560.03
+0.15%
Calvert Small/Mid-Cap C

AUPH and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AUPH has been loosely correlated with SHJBF. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if AUPH jumps, then SHJBF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUPH
1D Price
Change %
AUPH100%
+0.12%
SHJBF - AUPH
38%
Loosely correlated
N/A
KRYS - AUPH
37%
Loosely correlated
-2.60%
CRDF - AUPH
36%
Loosely correlated
-0.32%
NAMS - AUPH
35%
Loosely correlated
+0.65%
TGTX - AUPH
35%
Loosely correlated
-3.24%
More